These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 26714801)
1. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. Finkelmeier F; You SJ; Waidmann O; Wolff R; Zeuzem S; Bähr O; Trojan J J Gastrointest Cancer; 2016 Mar; 47(1):82-8. PubMed ID: 26714801 [TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Bhaskara A; Eng C Clin Colorectal Cancer; 2008 Jan; 7(1):65-8. PubMed ID: 18279580 [TBL] [Abstract][Full Text] [Related]
3. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab. Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166 [TBL] [Abstract][Full Text] [Related]
4. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer. Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185 [TBL] [Abstract][Full Text] [Related]
5. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study. Lu ZH; Peng JH; Wang FL; Yuan YF; Jiang W; Li YH; Wu XJ; Chen G; Ding PR; Li LR; Kong LH; Lin JZ; Zhang RX; Wan DS; Pan ZZ Medicine (Baltimore); 2016 Aug; 95(35):e4767. PubMed ID: 27583930 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A; Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453 [TBL] [Abstract][Full Text] [Related]
8. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Stathopoulos GP; Batziou C; Trafalis D; Koutantos J; Batzios S; Stathopoulos J; Legakis J; Armakolas A Oncology; 2010; 78(5-6):376-81. PubMed ID: 20798560 [TBL] [Abstract][Full Text] [Related]
9. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer]. Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446 [TBL] [Abstract][Full Text] [Related]
12. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience. Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N J BUON; 2013; 18(3):641-6. PubMed ID: 24065477 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816 [TBL] [Abstract][Full Text] [Related]
15. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290 [TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126 [TBL] [Abstract][Full Text] [Related]
17. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041 [TBL] [Abstract][Full Text] [Related]
18. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N Digestion; 2016; 94(3):129-137. PubMed ID: 27756074 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S; Oncology; 2013; 84(1):14-21. PubMed ID: 23076023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]